The global Wilson disease drugs market is expected to grow at a CAGR of 4.5% during the forecast period (2022-2028). Various strategies adopted by the key players and FDA-approved drugs for the treatment of Wilson's disease are supporting the growth of the global Wilson disease drugs market. For instance, in May 2022, the US FDA approved Cuvrior for the treatment of stable Wilson diseases in adults, who are decoppered and tolerant to penicillamine. The Cuvrior contains trientine, a copper chelator that eliminates absorbed copper from the human body by forming a stable complex, which is eliminated from urine excretion. Cuvrior is supplied as a functionally scored tablet containing 300mg of trientine tetrahydrochloride. The product is expected to be available in early 2023.
Browse the full report description of “Global Wilson Disease Drugs Market Size, Share and Trends Analysis Report, By Drug Type (Chelating Agents, Zinc, and Tetrathiomolybdate), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/wilson-disease-drugs-market
Vivet Therapeutics and Pfizer announced the US FDA has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson's disease in august 2021. VTX-801 is a novel investigational gene therapy, which is evaluated in a phase ½ clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the phase ½ clinical trial.
Further, in September 2019, the US FDA approved Kadmon Holdings, generic trientine hydrochloride capsules for the treatment of Wilson's disease patients who are intolerant of penicillamine. The US FDA has determined that Kadmon’s Trientine hydrochloride capsules are bioequivalent to the listed drug, Syprine Capsules 250 mg.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2021-2028
• Segment Covered-
o By Drug Type
o By Route of Administration
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Bausch Health Co. Inc., Nobelpharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., and Kadmon Holdings, Inc.
Key questions addressed by the report
• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Wilson Disease Drugs Market Report by Segment
By Drug Type
By Route of Administration
By Distribution Channel
Global Wilson Disease Drugs Market by Region
North America
• US
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/wilson-disease-drugs-market